Unveiling 9 Analyst Insights On 10x Genomics
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for 10x Genomics (NASDAQ:TXG) over the past three months, with a notable decline in the average 12-month price target. The company's financial metrics show positive revenue growth but challenges in profitability and returns.
June 03, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
10x Genomics (NASDAQ:TXG) has received mixed ratings from analysts, with a decline in the average 12-month price target to $39.0. The company shows positive revenue growth but faces challenges in profitability and returns.
The mixed analyst ratings and significant reduction in the average price target suggest a bearish short-term outlook for TXG. Despite positive revenue growth, the company's profitability challenges and lower returns contribute to a negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100